Combination therapy with gemcitabine in non-small cell lung cancer

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A M MosconiM Tonato

Abstract

The nucleoside analogue, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small cell lung cancer (NSCLC), producing consistent response rates of 20% and above. Because of its unique mechanism of action and its non-overlapping toxicity with other active agents, gemcitabine is an attractive candidate for trials in combination with other cytotoxic agents. In preclinical models, the cisplatin-gemcitabine combination suggested synergy between the two drugs. In phase I-II studies, response rates are as high as 54% when gemcitabine is combined with cisplatin, both in stage III and IV NSCLC. The combination of gemcitabine and ifosfamide is also being explored with an overall response rate of 32%. The gemcitabine-containing regimens showed a favourable safety-efficacy profile and compared well with standard regimens used in NSCLC. These preliminary results must be validated by large randomised trials comparing gemcitabine-containing regimens with NSCLC reference chemotherapy regimens.

References

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·J L Abbruzzese, P Frost
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H AndersonH H Hansen
Aug 17, 1993·Biochemical Pharmacology·V W Ruiz van HaperenG J Peters
Feb 1, 1996·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C Copley-MerrimanR C McDonald
Dec 1, 1995·Anti-cancer Drugs·M TonatoC Martin

❮ Previous
Next ❯

Citations

Mar 23, 2005·Mutation Research·Nilüfer AydemirRahmi Bilaloğlu
Mar 10, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T Le ChevalierJ Bérille
May 14, 2003·Mutation Research·Nilüfer Aydemir, Rahmi Bilaloğlu
Jul 27, 2002·The Lancet Oncology·Carlos M GalmariniCharles Dumontet
Feb 15, 2001·Japanese Journal of Cancer Research : Gann·M MatsumotoT Yoshioka
Sep 18, 2016·Mutation Research. Genetic Toxicology and Environmental Mutagenesis·Katsuyoshi HoribataMasamitsu Honma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
G CarteiG Tabaro
Expert Opinion on Investigational Drugs
W Tester, J Mora
© 2021 Meta ULC. All rights reserved